Regencell Bioscience Limited (RGC.US) saw its stock price jump more than 16% on Wednesday, reaching $26.70. The company is an early-stage biotechnology firm focused on the research, development, and commercialization of Traditional Chinese Medicine-based treatments for neurocognitive disorders and degenerative diseases, particularly ADHD and Autism Spectrum Disorder (ASD). In May of last year, market rumors suggested that Regencell had received FDA clinical trial approval for its next-generation neuromodulation chip and would collaborate with the top-tier medical institution Mayo Clinic on Parkinson's disease treatment research. The rumors also indicated that this neuromodulation chip technology represents a cutting-edge direction in the brain-computer interface field, with the company planning to use it to target a global market of approximately 10 million Parkinson's patients. Since its founding in 2014, Regencell Bioscience currently has no approved products, nothing available for sale, and has not generated any product revenue. The company previously stated that it does not expect to earn any revenue until its standardized TCM formulation products for ADHD and autism patients are commercialized in Hong Kong.